(1S,2R)-Bortezomib-d5
CAS : 1132709-16-0
Ref. 3D-HVB70916
5mg | Arrêté | ||
10mg | Arrêté | ||
25mg | Arrêté | ||
50mg | Arrêté | ||
100mg | Arrêté |
Informations sur le produit
(1S,2R)-Bortezomib-d5 is a modified form of bortezomib that has been radiolabeled with d5. It is an apoptotic agent that inhibits the proteasome pathway and induces apoptosis. Bortezomib-d5 has shown promising results in clinical trials for the treatment of lymphocytic leukemia, chronic lymphocytic leukemia, and multiple myeloma. The drug causes thrombocytopenia as a toxic effect.